Arvinas Inc
ARVN7.875USD
+0.644+8.92%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
541.80MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Unternehmen
Unternehmensinformationen
Unternehmens-codeARVN
Name des Unternehmens- -
IPO-datum- -
Gegründet am- -
CEO- -
Anzahl der mitarbeiter- -
WertpapierartOrdinary Share
Geschäftsjahresende- -
Addresse- -
Stadt- -
BörseNASDAQ Global Select Consolidated
Land- -
Postleitzahl- -
Telefon- -
Website- -
Unternehmens-codeARVN
IPO-datum- -
Gegründet am- -
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. John G. Houston, Ph.D.
Dr. John G. Houston, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
986.41K
+13.94%
Dr. Noah Berkowitz, M.D., Ph.D.
Dr. Noah Berkowitz, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
110.02K
-7.30%
Dr. Ian Taylor, Ph.D.
Dr. Ian Taylor, Ph.D.
President - Research and Development
President - Research and Development
105.53K
+12.35%
Dr. Angela Cacace
Dr. Angela Cacace
Chief Scientific Officer
Chief Scientific Officer
96.74K
+86.56%
Ms. Leslie V. Norwalk, Esq.
Ms. Leslie V. Norwalk, Esq.
Independent Director
Independent Director
5.90K
--
Mr. Everett V. Cunningham
Mr. Everett V. Cunningham
Independent Director
Independent Director
5.90K
--
Dr. Sunil Agarwal, M.D.
Dr. Sunil Agarwal, M.D.
Independent Director
Independent Director
5.90K
--
Mr. Jared Morris Freedberg
Mr. Jared Morris Freedberg
General Counsel
General Counsel
--
--
Dr. Laurie Smaldone Alsup, M.D.
Dr. Laurie Smaldone Alsup, M.D.
Independent Director
Independent Director
--
--
John Young ,
John Young ,
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. John G. Houston, Ph.D.
Dr. John G. Houston, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
986.41K
+13.94%
Dr. Noah Berkowitz, M.D., Ph.D.
Dr. Noah Berkowitz, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
110.02K
-7.30%
Dr. Ian Taylor, Ph.D.
Dr. Ian Taylor, Ph.D.
President - Research and Development
President - Research and Development
105.53K
+12.35%
Dr. Angela Cacace
Dr. Angela Cacace
Chief Scientific Officer
Chief Scientific Officer
96.74K
+86.56%
Ms. Leslie V. Norwalk, Esq.
Ms. Leslie V. Norwalk, Esq.
Independent Director
Independent Director
5.90K
--
Mr. Everett V. Cunningham
Mr. Everett V. Cunningham
Independent Director
Independent Director
5.90K
--
Umsatzaufteilung
FY2024
FY2023
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
United States
263.40M
0.00%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionäre
Update-Zeit: Fri, Feb 28
Update-Zeit: Fri, Feb 28
Aktionärsstatistik
Art
Aktionärsstatistik
Aktionäre
Anteil
The Vanguard Group, Inc.
11.46%
EcoR1 Capital, LLC
9.22%
BlackRock Institutional Trust Company, N.A.
7.24%
T. Rowe Price Associates, Inc.
5.51%
Citadel Advisors LLC
4.77%
Other
61.81%
Aktionärsstatistik
Aktionäre
Anteil
The Vanguard Group, Inc.
11.46%
EcoR1 Capital, LLC
9.22%
BlackRock Institutional Trust Company, N.A.
7.24%
T. Rowe Price Associates, Inc.
5.51%
Citadel Advisors LLC
4.77%
Other
61.81%
Art
Aktionäre
Anteil
Investment Advisor/Hedge Fund
40.57%
Investment Advisor
35.44%
Hedge Fund
18.71%
Corporation
4.76%
Venture Capital
3.17%
Research Firm
2.67%
Individual Investor
2.42%
Sovereign Wealth Fund
1.70%
Private Equity
1.52%
Institutionelle Beteiligung
Update-Zeit: Mon, Mar 3
Update-Zeit: Mon, Mar 3
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q1
493
81.65M
117.98%
-2.97M
2024Q4
505
80.31M
116.78%
-4.24M
2024Q3
496
79.95M
116.50%
-140.10K
2024Q2
489
78.26M
114.11%
+1.71M
2024Q1
494
75.44M
110.48%
+3.48M
2023Q4
497
68.16M
100.81%
+12.55M
2023Q3
472
52.04M
94.71%
-3.94M
2023Q2
473
53.77M
100.76%
-3.55M
2023Q1
475
55.60M
104.22%
-4.17M
2022Q4
484
56.43M
106.14%
-6.62M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
7.05M
10.26%
+56.56K
+0.81%
Dec 31, 2024
EcoR1 Capital, LLC
6.73M
9.78%
--
--
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
5.29M
7.69%
+152.31K
+2.97%
Dec 31, 2024
T. Rowe Price Associates, Inc.
4.02M
5.85%
+289.37K
+7.75%
Dec 31, 2024
Citadel Advisors LLC
3.48M
5.06%
+407.46K
+13.26%
Jan 30, 2025
Pfizer Inc
3.46M
5.03%
--
--
Dec 31, 2024
RTW Investments L.P.
3.33M
4.85%
+551.98K
+19.84%
Dec 31, 2024
Bellevue Asset Management AG
2.39M
3.47%
+3.00K
+0.13%
Dec 31, 2024
T. Rowe Price Investment Management, Inc.
2.21M
3.21%
+2.21M
--
Dec 31, 2024
UBS Financial Services, Inc.
2.01M
2.93%
+1.54M
+329.49%
Dec 31, 2024
Mehr Anzeigen
Verbundene ETFs
Update-Zeit: 10 hours ago
Update-Zeit: 10 hours ago
Name
Anteil
SPDR S&P Pharmaceuticals ETF
1.93%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.35%
Virtus LifeSci Biotech Clinical Trials ETF
0.86%
Range Cancer Immunotherapy ETF
0.49%
Tema Oncology ETF
0.39%
Federated Hermes MDT Small Cap Core ETF
0.19%
iShares U.S. Pharmaceuticals ETF
0.18%
Zacks Small/Mid Cap ETF
0.16%
JPMorgan Fundamental Data Science Small Core ETF
0.13%
Tema Neuroscience and Mental Health ETF
0.13%
Mehr Anzeigen
SPDR S&P Pharmaceuticals ETF
Anteil1.93%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Anteil1.35%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil0.86%
Range Cancer Immunotherapy ETF
Anteil0.49%
Tema Oncology ETF
Anteil0.39%
Federated Hermes MDT Small Cap Core ETF
Anteil0.19%
iShares U.S. Pharmaceuticals ETF
Anteil0.18%
Zacks Small/Mid Cap ETF
Anteil0.16%
JPMorgan Fundamental Data Science Small Core ETF
Anteil0.13%
Tema Neuroscience and Mental Health ETF
Anteil0.13%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten